Dapagliflozin plus gliclazide combination improves blood sugar control in type 2 diabetes
Key Takeaway:
Combining dapagliflozin with gliclazide improves blood sugar control more than dapagliflozin alone in type 2 diabetes.
Study at a Glance
What was studied
A trial of 244 Indian adults with type 2 diabetes testing combination therapy over 16 weeks
Study Type
Randomized Controlled Trials (RCTs)
duration
Short-Term (≤3 mo)
Intervention
Dapagliflozin Gliclazide combination, Dapagliflozin
Outcomes
HbA1c, Postprandial glucose, Hypoglycemia events
Funding
Industry Sponsored
Save this study and add notes to your research library.
Main Effects
HbA1c → ↓ (moderate improvement, additional 0.3% reduction)
Fasting blood sugar → ↓ (moderate improvement)
After-meal blood sugar → ↓ (moderate improvement)
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Dapagliflozin (Medications) |  HbA1c (Glycemic Control) | Decrease | Strong |
Dapagliflozin (Medications) |  Hypoglycemia events (Safety) | Uncertain | Strong |
Dapagliflozin Gliclazide combination (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Dapagliflozin Gliclazide combination (Medications) | Hypoglycemia events (Safety) | Increase | Limited |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- The combination of dapagliflozin plus gliclazide appears to lower HbA1c more than dapagliflozin alone in people taking metformin
- Fasting and after-meal blood sugar levels also improved more with the combination
- Low blood sugar events were uncommon and not serious
Who this applies to
Adults aged 18-65 with type 2 diabetes whose blood sugar remains poorly controlled (HbA1c 8-10%) despite taking metformin at adequate doses for at least 3 months. Does not apply to people with reduced kidney function, type 1 diabetes, or very high blood sugar levels.
Keep in Mind
Study participants were from India only, so results may not fully apply to other populations
Between the Lines
- Short 16-week study period
- Open-label design (not blinded)
- Excluded people with kidney problems
- Conducted only in India
Journal Reference
Erande SG, Raykantiwar A, Shejole V, et al. A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. Cureus. 2026;18(2):e103676. doi:10.7759/cureus.103676
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on SGLT2 Inhibitors and Glycemic Control, SGLT2 Inhibitors and Hypoglycemia.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Glycemic Control Evidence Hub
All studies measuring Glycemic Control
Measures Glycemic Control as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
Hypoglycemia Evidence Hub
All studies measuring Hypoglycemia
Measures Hypoglycemia as a key outcome.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Dapagliflozin and HbA1c
4 results
All studies on Dapagliflozin and Hypoglycemia events
1 results
All studies on Dapagliflozin
4 results
All studies measuring HbA1c
4 results
All studies measuring Hypoglycemia events
1 results
Questions this evidence helps answer
Key clinical and research questions this study contributes to.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.